Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.

ABSTRACT:

Aims/hypothesis

In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 diabetes.

Methods

Changes from baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed in the EMPA-REG OUTCOME^® trial (n = 7020), pooled data from four 24-week placebo-controlled trials (n = 2477) and a trial of empagliflozin vs glimepiride over 104 weeks (n = 1545). Analyses were performed using data from all participants and by tertiles of baseline aminotransferases.

Results

In the EMPA-REG OUTCOME^® trial, mean ± SE changes from baseline ALT at week 28 were -2.96 ± 

SUBMITTER: Sattar N 

PROVIDER: S-EPMC6133166 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature